BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
- Héritier, Sébastien
- Emile, Jean-François
- Barkaoui, Mohamed-Aziz
- Thomas, Caroline
- Fraitag, Sylvie
- Boudjemaa, Sabah
- Renaud, Florence
- Moreau, Anne
- Peuchmaur, Michel
- Chassagne-Clement, Catherine
- Dijoud, Frédérique
- Rigau, Valérie
- Moshous, Despina
- Lambilliotte, Anne
- Mazingue, Françoise
- Kebaili, Kamila
- Miron, Jean
- Jeziorski, Eric
- Plat, Geneviève
- Aladjidi, Nathalie
- Ferster, Alina
- Pacquement, Hélène
- Galambrun, Claire
- Brugières, Laurence
- Leverger, Guy
- Mansuy, Ludovic
- Paillard, Catherine
- Deville, Anne
- Armari-Alla, Corinne
- Lutun, Anne
- Gillibert-Yvert, Marion
- Stephan, Jean Louis
- Cohen-Aubart, Fleur
- Haroche, Julien
- Pellier, Isabelle
- Millot, Frédéric
- Lescoeur, Brigitte
- Gandemer, Virginie
- Bodemer, Christine
- Lacave, Roger
- Hélias-Rodzewicz, Zofia
- Taly, Valérie
- Geissmann, Frédéric
- Donadieu, Jean
Publication date
September 2016
DOI Publisher
American Society of Clinical Oncology (ASCO)Abstract
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia with a broad spectrum of clinical manifestations and outcomes in children. The somatic BRAF(V600E) mutation occurs frequently, but clinical significance remains to be determined.info:eu-repo/semantics/publishe
Add to ORKG